Aug. 4 at 12:05 PM
$LPCN
"We have requested a guidance meeting with the FDA and the meeting is scheduled for the third quarter of 2026. We have initiated
a new placebo controlled clinical trial for PPD to complement the existing LPCN 1154 clinical database, and to further
characterize the efficacy and safety of LPCN 1154."
Interesting that they have initiated a new study before the guidance meeting. I hope they already have some informal feedback indicating that will be the path forward. Assuming thats the case, its nice to see them getting the ball rolling so quickly.
